Akero Therapeutics' drug efruxifermin shows promise in reducing liver scarring in MASH patients.

In a mid-stage trial, 75% of patients on a higher dose saw scarring reduction, versus 24% with placebo.

The positive trial results sparked a 19% rise in Akero's stock price.

With no approved drugs for MASH, efruxifermin targets a market that could generate $2-3 billion in peak sales.

Over 17 million Americans are affected by MASH, indicating a significant market need.

The FDA is reviewing a competing drug, but Akero remains confident in efruxifermin's potential.

Multiple companies are in pursuit of MASH treatments, highlighting a competitive landscape.